http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Recent activity of mouse metabolic phenotyping service at Korea Mouse Phenotyping Center (KMPC)
Hye Sun Go,Ji Min Choi,Seul Gi Yoon,Su In Jang,Soo Jin Son,Da In On,Hyun A Noh,Mi Young Kim,Il Yong Kim,Je Kyung Seong 한국실험동물학회 2021 한국실험동물학회 학술발표대회 논문집 Vol.2021 No.7
To understand the function of individual genes is also a key information in developing new treatment techniques. Even though a couple of genetically engineered mouse (GEM) models has been generated, still precising determination of mouse phenotype is not easy. Precising mouse phenotyping is one of the effective way leading to discovery gene function. International Mouse Phenotyping Consortium (IMPC) has established mega database of mouse phenotyping data from different institutes across the world based on generalized platform. However more precised mouse phenotyping is still needed. In order to meet the need for more detailed phenoyping in mouse, Korea Mouse Phenotyping Center (KMPC), nation-wide program for mouse production and phenotyping in Korea has been establishing several pipelines for disease-specific mouse phenotyping to support the mouse research. Here we introduce mouse metabolic and exercise phenotyping services, as well as the other services of mouse research such as providing genetically engineered mouse information, producing selling genetically engineered mice, and managing resource quality so that researchers can easily utilize the research infrastructure. Metabolic characterization in mouse is one of key factors for understanding the pathogenesis of obesity, type 2 diabetes and insulin resistance. KMPC has been providing mouse metabolic phenotyping including high fat diet, exercise and cold challenges. Multiple parameter including energy expenditure (EE), O2/CO2 consumption (RER), heat generation and activity has been provided with histology service and body composition. Also temperature can be measured during metabolic chamber with telemetric system. Here we summarized mouse metabolic phenotyping services at KMPC.
Application of temperature-controlled metabolic chamber in mice
Su In Jang,Seul Gi Yoon,Hye Sun Go,Yong Jae Kim,Hak Su Kim,Ji Hyeon Baek,Tae Ho Kim,Ji Min Choi,Soo Kyung Kang,Da In On,Hyun A Noh,Il Yong Kim,Je Kyung Seong 한국실험동물학회 2021 한국실험동물학회 학술발표대회 논문집 Vol.2021 No.7
Recently, research on various metabolic diseases such as obesity and diabetes has been in the spotlight. A representative example of this is the study of metabolic function analysis using Metabolic cage. It is believed that these studies will greatly contribute to the prevention and treatment of various metabolic diseases in humans. This study focuses on the study of obesity in mice. Mouse metabolic phenotyping has been widely used for detecting metabolic disorder in genetically engineered mouse. Korea Mouse Phenotyping Center (KMPC), nation-wide program for mouse production and phenotyping in Korea has been establishing several pipelines for disease-specific mouse phenotyping to support the mouse research. KMPC has been providing mouse metabolic phenotyping including high fat diet, exercise and cold challenges. Multiple parameter including energy expenditure (EE), O2/CO2 consumption (RER), heat generation and activity has been provided with histology service and body composition. Also temperature can be measured during metabolic chamber with telemetric system. Brown adipogenesis is one of key mechanism for developing new candidate drug target for curing obesity and type 2 diabetes. Several factors including cold, adrenergic b3 agonist and exercise are well known factor leading to brown adipogenesis. Here we introduce mouse metabolic phenotyping services with environmental control chamber at KMPC. Temperature-controlled metabolic cage, the climate chambers can control temperatures from 4 °C to 35 °C, while measuring energy consumption using oxygen consumption, carbon dioxide production, and respiratory exchange ratio and food intake. Using this, exposing the mouse to a low temperature environment can activate BAT by browning WAT, which causes various diseases such as heart disease, diabetes, and obesity. The changes of metabolic parameter was finely measured during cold exposure with temperature-controlled metabolic cage.
( Hye Won Chung ),( June Gone Kim ),( Sang Ho Choi ),( Sun Young Lee ),( Young Hee Yoon ) 대한안과학회 2008 Korean Journal of Ophthalmology Vol.22 No.3
A 36-year old female with acute myelogenous leukemia presented with a sudden decrease in vision one month following bone marrow transplantation (BMT). She had been taking multiple immunosuppressants to treat her recently-developed graft-versus-host-disease (GVHD). Visual acuity was 20/60 in her right eye and 20/25 in her left. Ophthalmic examination revealed mild inflammatory reaction in both the anterior chamber and the vitreous of both eyes, as well as densely opaque yellow-white infiltrates with well-demarcated borders in the posterior retina of both eyes. She was originally diagnosed as CMV retinitis, but treatment with ganciclovir failed to improve her ocular condition. Subsequent work-up, including serology and brain MRI, led to a diagnosis of combined ocular and cerebral toxoplasmosis. After 6 weeks of antiparasitic therapy, her retinal lesions became inactive and her cerebral lesions improved. Immunosuppressed patients with necrotizing retinochoroiditis should be suspected of having toxoplasmosis. Accurate differentiation between this condition and CMV, and early intervention with the appropriate treatment may be critical to preserve the best vision.
The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal Vasculopathy
( Sun Young Lee ),( June Gone Kim ),( Soo Geun Joe ),( Hye Won Chung ),( Young Hee Yoon ) 대한안과학회 2008 Korean Journal of Ophthalmology Vol.22 No.2
Purpose: To evaluate the efficacy and safety of intravitreal bevacizumab for polypoidal choroidal vasculopathy (PCV). Methods: In this retrospective interventional pilot study, 12 eyes of 11 patients with active PCV were treated with intravitreal bevacizumab (1.25 mg) alone or in combination with photodynamic therapy (PDT) depending on the informed patient`s choice. Intravitreal bevacizumab was repeated at 6-week intervals until the regression of active lesion was detected on fluorescein angiography (FA) which was done on a regular basis, Indocyanine green angiography (ICGA) and optical coherence tomography (OCT) analyses. Results: Intravitreal bevacizumab was given alone in 8 eyes (Group 1) and in combination with PDT in 4 eyes (Group 2). Mean follow-up duration was 17 weeks in group 1 and 15 weeks in group 2 after bevacizumab treatment. The mean number of bevacizumab injections was 2.2 in group 1 and 2.5 in group 2. Mean BCVA improved from 20/63 to 20/40 in group 1 and 20/63 to 20/32 in group 2. Of all eyes, the BCVA improved by ≥2 lines in seven (58%) eyes and resolution of fluid and hemorrhages in clinical examination, an absence of leakage on repeat FAs, or resolved pigment epithelial detachment (PED) and/or subretinal fluid (SRF) on OCT exam was confirmed in 10 (83%) eyes. Partial or complete regression of the polypoidal vessels and interconnecting vessels was reported for most cases at the last follow-up. No significant ocular or systemic side effects were observed in both groups. Conclusions: Short-term results indicate that intravitreal bevacizumab (1.25 mg) alone or in combination with PDT is well tolerated and associated with improvement in BCVA and reduced angiographic leakage in most patients. Further evaluation of intravitreal bevacizumab therapy for the treatment of PCV is warranted.
Hye-Ja Chang,Jeong-Won Kim,Se-Young Ju,Eun-Sun Go 한국영양학회 2012 Nutrition Research and Practice Vol.6 No.4
In order to create a worker-friendly environment for institutional foodservice, facilities operating with a dry kitchen system have been recommended. This study was designed to compare the work safety and work environment of foodservice between wet and dry kitchen systems. Data were obtained using questionnaires with a target group of 303 staff at 57 foodservice operations. Dry kitchen facilities were constructed after 2006, which had a higher construction cost and more finishing floors with anti-slip tiles, and in which employees more wore non-slip footwear than wet kitchen (76.7%). The kitchen temperature and muscular pain were the most frequently reported employees’ discomfort factors in the two systems, and, in the wet kitchen, “noise of kitchen” was also frequently reported as a discomfort. Dietitian and employees rated the less slippery and slip related incidents in dry kitchens than those of wet kitchen. Fryer area, ware-washing area, and plate waste table were the slippery areas and the causes were different between the functional areas. The risk for current leakage was rated significantly higher in wet kitchens by dietitians. In addition, the ware-washing area was found to be where employees felt the highest risk of electrical shock. Muscular pain (72.2%), arthritis (39.1%), hard-of-hearing (46.6%) and psychological stress (47.0%) were experienced by employees more than once a month, particularly in the wet kitchen. In conclusion, the dry kitchen system was found to be more efficient for food and work safety because of its superior design and well managed practices.
Go, Younghoon,Jeong, Ji Yun,Jeoung, Nam Ho,Jeon, Jae-Han,Park, Bo-Yoon,Kang, Hyeon-Ji,Ha, Chae-Myeong,Choi, Young-Keun,Lee, Sun Joo,Ham, Hye Jin,Kim, Byung-Gyu,Park, Keun-Gyu,Park, So Young,Lee, Chul- American Diabetes Association 2016 Diabetes Vol.65 No.10
<P>Hepatic steatosis is associated with increased insulin resistance and tricarboxylic acid (TCA) cycle flux, but decreased ketogenesis and pyruvate dehydrogenase complex (PDC) flux. This study examined whether hepatic PDC activation by inhibition of pyruvate dehydrogenase kinase 2 (PDK2) ameliorates these metabolic abnormalities. Wildtype mice fed a high-fat diet exhibited hepatic steatosis, insulin resistance, and increased levels of pyruvate, TCA cycle intermediates, and malonyl-CoA but reduced ketogenesis and PDC activity due to PDK2 induction. Hepatic PDC activation by PDK2 inhibition attenuated hepatic steatosis, improved hepatic insulin sensitivity, reduced hepatic glucose production, increased capacity for beta-oxidation and ketogenesis, and decreased the capacity for lipogenesis. These results were attributed to altered enzymatic capacities and a reduction in TCA anaplerosis that limited the availability of oxaloacetate for the TCA cycle, which promoted ketogenesis. The current study reports that increasing hepatic PDC activity by inhibition of PDK2 ameliorates hepatic steatosis and insulin sensitivity by regulating TCA cycle anaplerosis and ketogenesis. The findings suggest PDK2 is a potential therapeutic target for nonalcoholic fatty liver disease.</P>